| Literature DB >> 29351887 |
Rong Jin1, Qiuxiang Chen2, Song Yao3, Encheng Bai1, Weitao Fu3, Ledan Wang4, Jiabing Wang3, Xiaojing Du1, Tao Wei5, Haineng Xu6, Chengxi Jiang6, Peihong Qiu3, Jianzhang Wu7, Wulan Li8, Guang Liang6.
Abstract
EF24 is an IKKβ inhibitor (IC50: 72 μM) containing various anti-tumor activities. In this study, a series of EF24 analogs targeting IKKβ were designed and synthesized. Several IKKβ inhibitors with better activities than EF24 were screened out and B3 showed best IKKβ inhibitory (IC50: 6.6 μM). Molecular docking and dynamic simulation experiments further confirmed this inhibitory effect. B3 obviously suppressed the viability of Hela229, A549, SGC-7901 and MGC-803 cells. Then, in SGC-7901 and MGC-803 cells, B3 blocked the NF-κB signal pathway by inhibiting IKKβ phosphorylation, and followed arrested the cell cycle at G2/M phase by suppressing the Cyclin B1 and Cdc2 p34 expression, induced the cell apoptosis by down-regulating Bcl-2 protein and up-regulating cleaved-caspase3. Moreover, B3 significantly reduced tumor growth and suppressed the IKKβ-NF-κB signal pathway in SGC-7901 xenograft model. In total, this study present a potential IKKβ inhibitor as anti-tumor precursor.Entities:
Keywords: Anti-tumor activity; IKKβ inhibitor; Molecular docking; Synthesis
Mesh:
Substances:
Year: 2017 PMID: 29351887 DOI: 10.1016/j.ejmech.2017.11.077
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514